Prograf + Tacrolimus Hexal
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Pharmacokinetics Study in de Novo Kidney Transplantation
Conditions
Pharmacokinetics Study in de Novo Kidney Transplantation
Trial Timeline
Oct 17, 2012 โ Aug 20, 2015
NCT ID
NCT01649427About Prograf + Tacrolimus Hexal
Prograf + Tacrolimus Hexal is a approved stage product being developed by Novartis for Pharmacokinetics Study in de Novo Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01649427. Target conditions include Pharmacokinetics Study in de Novo Kidney Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01649427 | Approved | Completed |
Competing Products
20 competing products in Pharmacokinetics Study in de Novo Kidney Transplantation